Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis

American Journal of Nephrology

Volumn 27, Issue 4, 2007, Pages 409-415

  Babazono, Tetsuya ^a   Nakamoto, Hidetomo ^b   Kasai, Kenji ^c   Kuriyama, Satoru ^d   Sugimoto, Tokuichiro ^e   Nakayama, Masaaki ^f   Hamada, Chieko ^g   Furuya, Ryuichi ^h   Hasegawa, Hirofumi ⁱ   Kasahara, Masato ^j   Moriishi, Misaki ^k   Tomo, Tadashi ^l   Miyazaki, Masanobu ^m   Sato, Manaka ⁿ   Yorioka, Noriaki ^o   Kawaguchi, Yoshindo ^p  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c Fuji City General Hospital   (Japan)

^d SAISEIKAI CENTRAL HOSPITAL   (Japan)

^e MITSUI MEMORIAL HOSPITAL   (Japan)

^f TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h Iwata City Hospital   (Japan)

ⁱ KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k TSUCHIYA GENERAL HOSPITAL   (Japan)

^l OITA UNIVERSITY   (Japan)

^m NAGASAKI UNIVERSITY HOSPITAL   (Japan)

ⁿ Baxter Limited   (Japan)

^o HIROSHIMA UNIVERSITY   (Japan)

^p Department of Obstetrics   (Japan)

more..

Author keywords

Automated peritoneal dialysis; Cholesterol; Continuous ambulatory peritoneal dialysis; Diabetic nephropathy; Hemoglobin A1C; Icodextrin; Triglyceride

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICODEXTRIN; INSULIN; IRON; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RECOMBINANT ERYTHROPOIETIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; JAPAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; CARBOHYDRATE METABOLISM; DIABETIC NEPHROPATHIES; DIALYSIS SOLUTIONS; FEMALE; GLUCANS; GLUCOSE; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY;

EID: 34447534484     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000105123     Document Type: Article

References (30)

1. United States Renal Data System: Annual Data Report, 2004. Minneapolis, USRDS Coordinating Center, 2004.
2. Gejyo F, Saito A, Akizawa T, et al: Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial 2004;5:443-459.
3. Kraus MA, Hamburger RJ: Is peritoneal dialysis the preferred modality in the diabetic patient? Adv Perit Dial 1996;12:89-92.
4. Babazono T, Miyamae M, Tomonaga O, Omori Y: Cardiovascular risk factors in diabetic patients undergoing continuous ambulatory peritoneal dialysis. Adv Perit Dial 1996;12:120-125.
5. Lee HB, Chung SH, Chu WS, Kim JK, Ha H: Peritoneal dialysis in diabetic patients. Am J Kidney Dis 2001;38(suppl 1):S200-S203.
6. Wu MS, Yu CC, Wu CH, Haung JY, Leu ML, Huang CC: Pre-dialysis glycemic control is an independent predictor of mortality in type II diabetic patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1999;19(suppl 2):S179-S183.
7. Morioka T, Emoto M, Tabata T, et al: Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001;24:909-913.
8. Little J, Phillips L, Russell L, Griffiths A, Russell GI, Davies SJ: Longitudinal lipid profiles on CAPD: their relationship to weight gain, comorbidity, and dialysis factors. J Am Soc Nephrol 1998;9:1931-1939.
9. Posthuma N, ter Wee PM, Donker AJ, Oe PL, Peers EM, Verbrugh HA; The Dextrin in APD in Amsterdam (DIANA) Group: Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. Perit Dial Int 2000;20(suppl 2):S106-S113.
10. Johnson DW, Arndt M, O'Shea A, Watt R, Hamilton J, Vincent K: Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload. BMC Nephrol 2001;2:2.
11. Marshall J, Jennings P, Scott A, Fluck RJ, McIntyre CW: Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 2003;64:1480-1486.
12. Hithaishi C, Lobbedez T, Padmanabhan S, Pineda ME, Oreopoulos DG: No beneficial effect of icodextrin on blood glucose control. Perit Dial Int 2004;24:199-200.
13. Martikainen T, Teppo AM, Gronhagen-Riska C, Ekstrand A: Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients. Blood Purif 2005;23:303-310.
14. Nakamura M, Taniguchi Y, Yamamoto M, Hino K, Manabe M: Homologous assay for LDL-cholesterol on an automatic analyzer. Clin Chem 1997;43:260-261.
15. Grodstein GP, Blumenkrantz MJ, Kopple JD, Moran JK, Coburn JW: Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int 1981;19:564-567.
16. Collier RO Jr, Baker FB: Some Monte Carlo results on the power of the F-test under permutation in the simple randomized block design. Biometrika 1966;53:199-203.
17. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R: Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int 2001;21:275-281.
18. Moberly JB, Mujais S, Gehr T, et al: Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int 2002;62(suppl 81):S23-S33.
19. Gokal R, Moberly J, Lindholm B, Mujais S: Metabolic and laboratory effects of icodextrin. Kidney Int 2002;62(suppl 81):S62-S71.
20. Gradden CW, Ahmad R, Bell GM. Peritoneal dialysis: new developments and new problems. Diabet Med 2001;18:360-363.
21. Camargo JL, Gross JL: Conditions associated with very low values of glycohemoglobin measured by an HPLC method. J Clin Pathol 2004;57:346-349.
22. Nakao T, Matsumoto H, Okada T, et al: Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 1998;37:826-830.
23. Herruer MH, van Kooten EA, Sluiter HE, Zuijderhoudt FM: Influence of uremia on the determination of blood glycohemoglobin by HPLC, electrophoresis and affinity chromatography in diabetic and non-diabetic patients. Eur J Clin Chem Clin Biochem 1994;32:361-364.
24. Lamb E, Venton TR, Cattell WR, Dawnay A: Serum glycated albumin and fructosamine in renal dialysis patients. Nephron 1993;64:82-88.
25. Attman PO, Samuelsson O, Johansson AC, Moberly JB, Alaupovic P: Dialysis modalities and dyslipidemia. Kidney Int 2003;63(suppl 84):S110-S112.
26. Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alaupovic P: Alterations in lipoprotein composition in peritoneal dialysis patients. Perit Dial Int 2002;22:220-228.
27. Sisca S, Maggiore U: Beneficial effect of icodextrin on the hypertriglyceridemia of CAPD patients. Perit Dial Int 2002;22:727-729.
28. Wheeler DC: Abnormalities of lipoprotein metabolism in CAPD patients. Kidney Int 1996;50(suppl 56):S41-S46.
29. Teno S, Uto Y, Nagashima H, et al: Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care 2000;23:1401-1406.
30. Iso H, Naito Y, Sato S, et al: Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 2001;153:490-499.